Johnson & Johnson COVID Vaccine Pause Lifted

Apr 26, 2021

COVID-19 Announcement: Nurse-Led COVID Vaccine Confidence Project

Last Friday (4/23), the CDC’s Advisory Committee on Immunization Practices (ACIP), reviewed 15 cases of rare blood clots, thrombosis with thrombocytopenia syndrome (TTS), that occurred following administration of the Janssen (Johnson & Johnson) COVID-19 vaccine.

"Based on an in-depth analysis, there is likely an association but the risk is very low. What we are seeing is the overall rate of events was 1.9 cases per million people. In women 18 to 49 years, there was an approximate 7 cases per million."
CDC Director Dr. Rochelle Walensky

ACIP voted 10-4 to recommend lifting the temporary, 10-day pause of use of the J&J vaccine. Following that recommendation, CDC and FDA lifted the pause.

Tomorrow (4/27), CDC’s Clinician Outreach and Communication Activity (COCA) Call will discuss information on TTS and updated vaccine recommendations. This webinar is scheduled for Tuesday, April 27 from 2:00 - 3:00pm Eastern Time.

 Click here to join the 4/27 CDC Meeting 


These TTS cases were detected through the Vaccine Adverse Events Reporting System (VAERS)Reminder that healthcare providers are required by law to report any adverse event to VAERS.



Stay Connected with Nurse-Led Care